Pro-IV

Company Overview

Snapshot

Founded in November 2006 by Jacob Nusbacher, Pierre Sharvit, Gershon Goldenberg, and Michal Devir, Pro-IV operated with 1–10 employees. The company raised $415K across one funding round from one investor. In October 2020, Pro-IV ceased operations.

Business overview

Pro-IV developed a mobile platform designed to manage and monitor patients undergoing infusion therapy at home or in clinical settings. Its core technology, the Intravenous Monitoring, Management, and Error-prevention (IMMAGINE) system, aimed to enhance patient safety by reducing bedside errors in IV drug therapy and blood transfusions. The system also focused on improving the accuracy, monitoring, and documentation of electronic patient data within various clinical environments, serving the healthcare industry and patients in the digital healthcare sector.

Strategic signal

Pro-IV ceased operations in October 2020, indicating a significant strategic shift and the conclusion of its efforts in developing mobile platforms for infusion therapy management. This event signals to investors and innovation teams the company's inability to sustain its business model or achieve market viability, despite its initial focus on patient safety and error prevention in healthcare.

Company Intelligence Q&A

What is Pro-IV's primary focus?

Pro-IV focuses on developing mobile platforms to manage and monitor patients receiving infusion therapy, aiming to prevent errors and improve safety in both home and hospital settings.

When was Pro-IV founded?

Pro-IV was founded in November 2006.

Who are the founders of Pro-IV?

Pro-IV was founded by Jacob Nusbacher, Pierre Sharvit, Gershon Goldenberg, and Michal Devir.

What was the total disclosed funding raised by Pro-IV?

Pro-IV raised a total of $415K across one funding round. This funding was a Seed round in November 2006 from The Trendlines Group.

What is the status of Pro-IV?

Pro-IV is non-active and ceased to operate in October 2020.